Parkinson's Disease - 5EU Drug Forecast and Market Analysis to 2022: Introduction of A2A antagonists in 2019, will bring in an extra $24.7m in sales in 2022
M2 - Thu May 15, 10:54AM CDT
Research and Markets (http://www.researchandmarkets.com/research/8h86cj/pharmapoint) has announced the addition of the "PharmaPoint: Parkinson's Disease - 5EU Drug Forecast and Market Analysis to 2022" report to their offering. Although France has a lower-than-average rate of generic substitution compared with other parts of Europe, increasing pressures from its aging population and increased disease burden are forcing governments to institute cost-saving measures. The market leader therapies in Germany are all no longer patent protected and include the class of oral dopamine agonists. While the overall pharmaceutical market in Italy is shrinking, the medical device market in Italy is growing. This market growth will be driven by six new product launches, and by an aging population, resulting in an increased prevalence of Parkinson's disease in Spain. Population growth and the aging population will continue to build steady growth in the UK Parkinson's disease market and six additional product launches, including the introduction of A2A antagonists in 2019, will bring in an extra $24.7m in sales in 2022. Scope - Overview of Parkinson's Disease including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape. - Detailed information on the key drugs in 5EU including product description, safety and efficacy profiles as well as a SWOT analysis. - Sales forecast for the top drugs in 5EU from 2012-2022. - Analysis of the impact of key events as well the drivers and restraints affecting the 5EU Parkinson's Disease market. Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Disease Overview - Etiology and Pathophysiology - Symptoms 4 Disease Management - Treatment Synopsis - Parkinson's Disease Assessment Scales - Diagnosis and Treatment of Parkinson's Disease by Country 5 Competitive Assessment - Product Profiles - Levodopa Combination Therapy - Product Profiles - COMT Inhibitors - Dopamine Agonists - Product Profiles - MAO-B Inhibitors - Product Profiles - Adenosine 2A Inhibitor - Product Profiles - Other Therapies 6 Opportunity and Unmet Need - Treatment of Motor Complications - Dyskinesias and OFF Episodes - Treatment of Non-Motor Symptoms and Dementia - Neuroprotective/Disease-Modifying Agents - Improved Drug Formulations - Identification of Reliable Biomarkers - Improved Clinical Trial Design 7 Pipeline Assessment - Safinamide - Tozadenant - CVT-301 - Rytary/IPX066 - Opicapone - Mavoglurant/AFQ056 - CD/LD-GR - Other Late-Stage Pipeline Products 8 Current and Future Players - Merck - Roche - AbbVie - UCB - GlaxoSmithKline - Novartis - Orion - Newron - Civitas - Impax - Lundbeck 9 Market Outlook - Driver: Aging Population - Driver: Launch of Products that Will Add Patient Share - Driver: High Compliance Rates - Driver: History of Success in PD Market - Driver: Innovation and Technological Advances - Driver: High Degree of Polypharmacy - Barrier: Lack of Understanding of Pathophysiology - Barrier: Lack of Efficacy of New Compounds - Barrier: Strategic Decisions to Leave CNS Space for Several Large Pharma Companies 10 Appendix For more information visit http://www.researchandmarkets.com/research/8h...harmapoint
Purdue Pharma Canada announces the appointment of Grant D. Perry as Vice President of Government and Corporate Affairs
CNW Group - Thu May 15, 10:24AM CDT
Purdue Pharma Canada today announced the appointment of Grant Perry to the position of Vice President, Government and Corporate Affairs, effective May 15, 2014. In this role, Mr. Perry will also be responsible for the development and implementation of strategies to ensure appropriate patient access to Purdue's current and future marketed products. Mr. Perry reports to Dr. Craig Landau, President and CEO, and will be a key member of Purdue's executive leadership team.
Up 31%: Why Pernix Therapeutics Surprised Investors
Michael Douglass and David Williamson, The Motley Fool - Motley Fool - Thu May 15, 10:01AM CDT
Shares of Pernix Therapeutics soared 31% yesterday after the company revealed that it had bought the U.S. rights to GlaxoSmithKline 's Treximet (which helps treat migraines in adults) for $250 million upfront (and some potential additional...
Isis Pharmaceuticals Earns $3.0 Million from GSK
PR Newswire - Thu May 15, 6:00AM CDT
Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has earned a $3.0 million milestone payment from GlaxoSmithKline (GSK) related to the initiation of a natural history study, which will support the advancement of one of the alliance programs.
SFW Capital Partners Makes a Strategic Investment in Essen BioScience
Business Wire - Thu May 15, 5:00AM CDT
SFW Capital Partners, a specialized private equity firm that invests with management in mid-sized companies providing analytical tools and related services, today announced an investment in Essen BioScience, Inc. SFW is partnering in this investment with Essen's co-founders, Kirk Schroeder and Brad Neagle, who serve as the current President and Vice-President of Operations and Engineering respectively, and its management team. As a team, the partners at SFW have supported some of the most successful and well-regarded companies in the analytical instrumentation market, including Mettler-Toledo International, Waters Corporation, Spectro Scientific and Industrial Dynamics Company ("filtec"
How Will GlaxoSmithKline's (GSK) Stock Be Affected By Chinese Bribery Accusations?
at The Street - Wed May 14, 1:38PM CDT
GlaxoSmithKline's (GSK) former China chief was accused by Chinese authorities today of ordering his subordinates and other employees to bribe hospital doctors, health-care organizations and other parties on "a large scale" to boost Glaxo's drug sales...
Global Meningococcal Vaccines Market 2013 - 2019 - Polysaccharide, Conjugate, and Combination Vaccines, along with Pipeline Analysis
M2 - Wed May 14, 8:05AM CDT
Research and Markets (http://www.researchandmarkets.com/research/bwh98b/meningococcal) has announced the addition of the "Meningococcal Vaccines Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019" report to their offering. The key players contributing to the global meningococcal vaccines market include Sanofi SA, Novartis AG, GSK plc, Pfizer, Inc., Nuron Biotech, JN International Medical Corporation, Serum Institute of India Ltd., Baxter International and Biomed Pvt. Ltd. The global meningococcal vaccines market is segmented broadly into polysaccharide, conjugate and combination vaccines. These vaccine types are further segmented into different brands available in the market. Polysaccharide vaccines is the oldest type available in market since last three decades. However, the presence and widespread use of conjugate vaccines has drastically reduced the incidences of bacterial meningitis due to the prolonged immunity achieved against the disease-causing serogroups, unlike polysaccharide vaccines which provide immunity for a very short period. Combination vaccines against invasive meningococci in combination with other organisms such as pneumococcal and Haemophilus influenzae type B are considered as new weapons to fight against two bacterial infections. This has shown to reduce the number of injections needed to be administered when compared to their individual doses. Hence, combination vaccines are likely to have high growth in forthcoming years. The notable pipeline vaccines against meningococcal disease include Bexsero by Novartis, MnB rLP2806 by Pfizer and NmVac4-DT by JN International Medical Corporation. Novartis in January 2013, received marketing authorization for Bexsero as the only vaccine against serogroup B, across the European Union, Canada and Australia, and has been currently filed for U.S. FDA licensure. The rLP2806 vaccine, is currently in phase III clinical trials and has been granted Breakthrough Therapy Status by the U.S. FDA in 2014. NmVac4 DT, on the other hand, has been developed against the broad range of (quadrivalent) serogroups A, C, Y and W-135. Moreover, its manufacturer of the vaccine JN International Medical Corporation claims the vaccine to be animal component free, which is expected to be the major driver for its demand post market launch. Major growth drivers for the global meningococcal vaccines market include favourable public-private partnerships to support development of vaccines at low cost, and the medical emergency status of the disease. Increase in the demand for vaccines and number of people getting immunized has been majorly contributed to the education and awareness campaigns conducted by manufacturers as well as non-profit organizations in the developed economies. Government intervention such as approval of legislations to mandate immunization programs for school children up to a certain age, and stringent regulations for Hajj pilgrims and sub-Saharan travellers also contribute positively to this market due to increased demand for these vaccines from the non-profit organizations. The global meningococcal vaccines market is segmented as follow: Companies Mentioned - Baxter International, Inc. - Biomed Pvt. Ltd. - GlaxoSmithKline plc - JN-International Medical Corporation - Novartis International AG - Nuron Biotech, Inc. - Pfizer, Inc. - Sanofi SA - Serum Institute of India Ltd. Polysaccharide Vaccines, by Brand - Menomune - Mencevax - NmVac4 - Others -- Quadri Meningo -- Bi Meningo Conjugate Vaccines, by Brand - Menactra - Menveo - NeisVac-C - Nimenrix - Meningitec - Menjugate - MenAfriVac Combination Vaccines, by Brand - MenHibrix - Menitorix Pipeline Vaccines, by Brand - Bexsero - MnB rLP2806 - NmVac4-DT For more information visit http://www.researchandmarkets.com/research/bw...ingococcal
May 14 Premarket Briefing: 10 Things You Should Know
at The Street - Wed May 14, 7:01AM CDT
U.S. stock futures are flat; Sony posts a $1.3 billion quarterly loss; Cisco reports earnings after Wednesday's closing bell; Sears considers selling its Canada operations.
PERNIX Signs Agreement to Acquire TREXIMET(R) Tablets for Migraine From GSK
Business Wire - Wed May 14, 6:30AM CDT
Pernix Therapeutics Holdings, Inc. (NASDAQ GM: PTX) ("Pernix" or the "Company"
POZEN Announces U.S. Rights for Treximet(R) to Be Acquired by Pernix Therapeutics
Business Wire - Wed May 14, 6:30AM CDT
POZEN Inc. (NASDAQ: POZN), a pharmaceutical company committed to transforming medicine that transforms lives, today announced that GlaxoSmithKline (GSK) will divest all of its rights to Treximet(R) (sumatriptan / naproxen sodium) to Pernix Therapeutics Holdings, Inc. (Pernix). As part of the Divestiture, GSK will assign the Product Development and Commercialization Agreement between POZEN and GSK to Pernix, and POZEN and Pernix will amend the agreement to address rights of the parties and future development.
European Stocks Move Slightly Lower; Asian Shares Are Mixed
at The Street - Wed May 14, 5:26AM CDT
European markets are subdued Wednesday. Asian stocks finish mixed
The ASCO Abstracts Are Coming
Brian Orelli, The Motley Fool - Motley Fool - Tue May 13, 5:45PM CDT
The American Society for Clinical Oncology annual meeting doesn't start until the end of this month, but investors will get a little sneak peek of what to expect when abstracts for the meeting are released at 5 p.m. Eastern on Wednesday. In the...
Harris & Harris Group Notes Metabolon's Collaboration With GSK
GlobeNewswire - Tue May 13, 11:43AM CDT
Harris & Harris Group, Inc. (Nasdaq:TINY), an investor in transformative companies enabled by disruptive science, notes the announcement by portfolio company, Metabolon, Inc., that it has entered into a collaboration agreement with GlaxoSmithKline ("GSK"
Is GlaxoSmithKline's Dividend Unbeatable?
Dan Carroll, The Motley Fool - Motley Fool - Tue May 13, 10:58AM CDT
Big pharma's home to some of the highest-yielding blue chip stocks on the market, but few offer dividend investors more than GlaxoSmithKline . Glaxo's 4.5% dividend and manageable payout ratio make this stock a boon for long-term investors, but...
Metabolon Enters into Collaboration with GSK
Business Wire - Tue May 13, 10:08AM CDT
Metabolon, Inc., a leading diagnostics and research services company offering metabolomics research platforms, has entered into a collaboration with GlaxoSmithKline (GSK) to provide metabolomic profiling services and to collaborate on other research projects leveraging Metabolon's leading DiscoveryHD4(TM) platform.
Busy Days Ahead for Sarepta Therapeutics
George Budwell, The Motley Fool - Motley Fool - Mon May 12, 11:23AM CDT
Shares of the clinical-state biotech Sarepta Therapeutics have certainly been on a wild ride over the past year. And the underlying cause of this volatility has undoubtedly been the regulatory and clinical uncertainty regarding the company's...
Global Pulmonary Drug Delivery Systems Market 2013-2019: Metered Dose Inhalers, Dry Powder Inhalers and Nebulizers
M2 - Mon May 12, 9:11AM CDT
Research and Markets (http://www.researchandmarkets.com/research/ntkzm3/pulmonary_drug) has announced the addition of the "Global Pulmonary Drug Delivery Systems Market 2013-2019: Metered Dose Inhalers, Dry Powder Inhalers and Nebulizers" report to their offering. The market size and forecast for each region has been provided for the period 2011 to 2019 along with the CAGR (%) for the forecast period 2013 to 2019. The study also includes qualitative analysis of the competitive scenario in these regions. The market overview section of the report comprises qualitative analysis of the overall market considering the factors determining the market dynamics such as drivers, restraints and opportunities, along with Porter's five force analysis and market attractiveness analysis. This report studies the current scenario as well as the future market potential for pulmonary drug delivery systems, globally. The market for pulmonary drug delivery systems has been segmented into three major product types, namely, metered dose inhalers (MDIs), dry powder inhalers (DPIs) and nebulizers. The market for these systems has been extensively analyzed on the basis of factors such as therapeutic application, geographic presence and technological developments. On the basis of therapeutic application, the market has been segmented into asthma, chronic obstructive pulmonary disease (COPD) and cystic fibrosis. The market size and forecasts in terms of revenue (USD million) for each of these segments have been provided for the period 2011 to 2019, considering 2012 as the base year. The report also provides the compounded annual growth rate (CAGR) for each segment of the market for the forecast period 2013 to 2019. The report also provides a section on the competitive landscape of the market, wherein the market share analysis of leading players in the global pulmonary drug delivery systems market, in terms of percentage share in 2012 has been discussed. A list of recommendations has also been included for new entrants as well as existing market players to help them establish a strong presence in the market and accentuate market shares. Scope Pulmonary Drug Delivery Systems Market, by Product Type - Metered Dose Inhalers (MDIs) - Dry Powder Inhalers (DPIs) - Nebulizers Pulmonary Drug Delivery Systems Market, by Application - Asthma - Chronic Obstructive Pulmonary Disease (COPD) - Cystic Fibrosis Companies Mentioned - 3M Health Care - Allied Healthcare Products, Inc. - AstraZeneca plc - Boehringer Ingelheim - CareFusion Corporation - GF Health Products, Inc. - GlaxoSmithKline plc - Merck & Co., Inc. - Novartis AG - Omron Healthcare, Inc. - PARI Respiratory Equipment, Inc. - Philips Healthcare - Sunovion Pharmaceuticals Inc. For more information visit http://www.researchandmarkets.com/research/nt...onary_drug
Earnings Results, Agreements, Study Results, FDA Approvals, and Drug Trial Results - Analyst Notes on Merck, Johnson & Johnson, GlaxoSmithKline, Novartis and Intercept
PR Newswire - Mon May 12, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Merck & Co. Inc. (NYSE: MRK), Johnson & Johnson (NYSE: JNJ), GlaxoSmithKline plc (NYSE: GSK), Novartis AG (NYSE: NVS) and Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/2305-100free.
How This 1 Company Is Attempting to Overcome One of Cancer's Greatest Risk Factors
Sean Williams, The Motley Fool - Motley Fool - Sat May 10, 1:05PM CDT
Cancer is one of the scariest disease diagnoses imaginable, at least according to one U.K. study , and that's primarily because researchers, despite decades of work and collaboration, are still scratching the surface on what triggers cancer in the...